{"id":"decitabine-and-cedazuridine","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (anemia, thrombocytopenia, neutropenia)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Febrile neutropenia"}]},"_chembl":null,"_dailymed":{"setId":"91a0f80b-f865-4d06-a40d-4d148d99ee71","title":"INQOVI (CEDAZURIDINE AND DECITABINE) TABLET, FILM COATED [TAIHO PHARMACEUTICAL CO., LTD.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Decitabine is a hypomethylating agent that inhibits DNA methyltransferase, leading to demethylation of DNA and reactivation of epigenetically silenced genes including tumor suppressors. Cedazuridine is a cytidine deaminase inhibitor that prevents the rapid degradation of decitabine, enabling effective oral bioavailability of the combination. This allows decitabine to exert its anti-neoplastic effects in hematologic malignancies.","oneSentence":"Decitabine inhibits DNA methyltransferase to reactivate silenced tumor suppressor genes, while cedazuridine protects decitabine from deamination, allowing oral administration.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:31:47.644Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Myelodysplastic syndromes (MDS)"},{"name":"Acute myeloid leukemia (AML)"}]},"trialDetails":[{"nctId":"NCT05600894","phase":"PHASE2","title":"Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-06-27","conditions":"Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts","enrollment":132},{"nctId":"NCT06661915","phase":"PHASE2","title":"A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-08-14","conditions":"Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm, Essential Thrombocythemia","enrollment":62},{"nctId":"NCT06802523","phase":"PHASE1","title":"Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-21","conditions":"Acute Myeloid Leukemia","enrollment":53},{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT07012044","phase":"PHASE1","title":"A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-10-30","conditions":"Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":47},{"nctId":"NCT04340843","phase":"PHASE2","title":"Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-09-08","conditions":"Locally Advanced Unresectable Primary Central Chondrosarcoma, Metastatic Primary Central Chondrosarcoma, Unresectable Primary Central Chondrosarcoma","enrollment":19},{"nctId":"NCT05272384","phase":"PHASE1","title":"Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-03","conditions":"Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma","enrollment":32},{"nctId":"NCT06672146","phase":"PHASE2","title":"Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-05-16","conditions":"Acute Myeloid Leukemia","enrollment":93},{"nctId":"NCT07437950","phase":"PHASE2","title":"Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-10-14","conditions":"Acute Myeloid Leukemia","enrollment":126},{"nctId":"NCT07153497","phase":"PHASE2","title":"Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-05-27","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":132},{"nctId":"NCT06577441","phase":"PHASE2","title":"Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-12","conditions":"Myelodysplastic Syndrome","enrollment":54},{"nctId":"NCT05673200","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-09-25","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma","enrollment":32},{"nctId":"NCT05960773","phase":"PHASE2","title":"Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2024-01-31","conditions":"Mesothelioma, Malignant Mesothelioma (MM), Early-stage Mesothelioma","enrollment":9},{"nctId":"NCT04742634","phase":"PHASE1, PHASE2","title":"Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2022-05-12","conditions":"Myelodysplastic Syndromes","enrollment":209},{"nctId":"NCT05636514","phase":"PHASE1","title":"Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS","status":"RECRUITING","sponsor":"Clinical Hub for Interventional Research (CHOIR)","startDate":"2022-12-14","conditions":"Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia","enrollment":12},{"nctId":"NCT07472322","phase":"PHASE1, PHASE2","title":"ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1","status":"NOT_YET_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2026-04","conditions":"Merkel Cell Carcinoma, Merkel Cell Carcinoma, Stage III, Merkel Cell Carcinoma, Stage IV","enrollment":31},{"nctId":"NCT06484062","phase":"PHASE1","title":"Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-08-15","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome/Acute Myeloid Leukemia","enrollment":54},{"nctId":"NCT04746235","phase":"PHASE2","title":"Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-02-22","conditions":"Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":85},{"nctId":"NCT03502668","phase":"PHASE1, PHASE2","title":"Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS","status":"COMPLETED","sponsor":"Taiho Oncology, Inc.","startDate":"2018-07-27","conditions":"Myelodysplastic Syndromes","enrollment":160},{"nctId":"NCT04953897","phase":"PHASE1","title":"Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment","status":"RECRUITING","sponsor":"Taiho Oncology, Inc.","startDate":"2021-12-15","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":18},{"nctId":"NCT04953910","phase":"PHASE1","title":"Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment","status":"RECRUITING","sponsor":"Taiho Oncology, Inc.","startDate":"2022-12-23","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":27},{"nctId":"NCT07148947","phase":"PHASE2","title":"Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-03-02","conditions":"Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm","enrollment":27},{"nctId":"NCT06297629","phase":"PHASE2","title":"A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-07-01","conditions":"Allogeneic Stem Cell Transplantation","enrollment":""},{"nctId":"NCT04061421","phase":"PHASE1, PHASE2","title":"Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)","status":"RECRUITING","sponsor":"Michael Savona","startDate":"2021-11-24","conditions":"MDS/MPN","enrollment":94},{"nctId":"NCT05403450","phase":"PHASE1","title":"A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Taiho Oncology, Inc.","startDate":"2023-02-22","conditions":"Relapsed/Refractory Peripheral T-cell Lymphoma","enrollment":33},{"nctId":"NCT05010122","phase":"PHASE1, PHASE2","title":"ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-07-08","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia","enrollment":42},{"nctId":"NCT05007873","phase":"PHASE2","title":"ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-10-21","conditions":"Chronic Phase Chronic Myelogenous Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia","enrollment":70},{"nctId":"NCT06191978","phase":"PHASE1","title":"A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-03-07","conditions":"Acute Myeloid Leukemia","enrollment":40},{"nctId":"NCT04655755","phase":"PHASE1, PHASE2","title":"Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-01-19","conditions":"Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome","enrollment":52},{"nctId":"NCT06284460","phase":"PHASE1, PHASE2","title":"Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-01-31","conditions":"Pathway Mutant Myelodysplastic Syndromes, Myelodysplastic Neoplasm, Myeloproliferative Neoplasm","enrollment":""},{"nctId":"NCT04872543","phase":"PHASE2","title":"A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-04-29","conditions":"Malignant Peripheral Nerve Sheath Tumors (MPNST)","enrollment":25},{"nctId":"NCT06177171","phase":"PHASE1","title":"Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors","status":"RECRUITING","sponsor":"Pamela Munster","startDate":"2024-02-07","conditions":"BRCA1 Mutation, BRCA2 Mutation, BRCA Mutation","enrollment":18},{"nctId":"NCT06091267","phase":"PHASE1, PHASE2","title":"PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Otsuka Beijing Research Institute","startDate":"2023-10-16","conditions":"Myelodysplastic Syndromes","enrollment":72},{"nctId":"NCT05010772","phase":"PHASE1","title":"Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-10-25","conditions":"Acute Myeloid Leukemia","enrollment":125},{"nctId":"NCT03875287","phase":"PHASE1","title":"Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2019-04-17","conditions":"Solid Tumor","enrollment":35},{"nctId":"NCT05799079","phase":"PHASE2","title":"Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant","status":"TERMINATED","sponsor":"Sanjay Mohan","startDate":"2023-04-13","conditions":"Recurrent Acute Myeloid Leukemia","enrollment":1},{"nctId":"NCT06327685","phase":"PHASE1","title":"Avapritinib With Decitabine in Patients With SM-AHN","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-03-13","conditions":"Systemic Mastocytosis With an Associated Hematologic Neoplasm","enrollment":34},{"nctId":"NCT05201066","phase":"PHASE2","title":"Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-02-13","conditions":"Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic","enrollment":33},{"nctId":"NCT03613532","phase":"PHASE1","title":"Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jacqueline Garcia, MD","startDate":"2018-10-24","conditions":"Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML)","enrollment":102},{"nctId":"NCT04245397","phase":"PHASE1","title":"Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"Syntrix Biosystems, Inc.","startDate":"2020-06-30","conditions":"Myelodysplastic Syndromes","enrollment":151},{"nctId":"NCT03922555","phase":"PHASE1","title":"ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2019-07-12","conditions":"Neurological Cancer","enrollment":18},{"nctId":"NCT04657081","phase":"PHASE1, PHASE2","title":"Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Taiho Oncology, Inc.","startDate":"2021-02-09","conditions":"Acute Myeloid Leukemia","enrollment":101},{"nctId":"NCT05089370","phase":"PHASE1, PHASE2","title":"Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2022-06-20","conditions":"Malignant Melanoma","enrollment":8},{"nctId":"NCT05918055","phase":"PHASE1, PHASE2","title":"Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2023-11-14","conditions":"Myelodysplastic Syndromes","enrollment":3},{"nctId":"NCT05178693","phase":"PHASE1","title":"Lutathera and ASTX727 in Neuroendocrine Tumours","status":"RECRUITING","sponsor":"Imperial College London","startDate":"2022-04-25","conditions":"Neuroendocrine Tumors","enrollment":27},{"nctId":"NCT05037500","phase":"PHASE1","title":"Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2022-01-26","conditions":"Castration-Resistant Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8","enrollment":8},{"nctId":"NCT04817241","phase":"PHASE1, PHASE2","title":"Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-02-10","conditions":"Acute Myeloid Leukemia","enrollment":5},{"nctId":"NCT04774393","phase":"PHASE1, PHASE2","title":"Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-05-24","conditions":"Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":84},{"nctId":"NCT04093570","phase":"PHASE2","title":"A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)","status":"ENROLLING_BY_INVITATION","sponsor":"Taiho Oncology, Inc.","startDate":"2019-09-30","conditions":"Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes","enrollment":332},{"nctId":"NCT04975919","phase":"PHASE2","title":"Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-09-29","conditions":"Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Biphenotypic Leukemia","enrollment":20},{"nctId":"NCT06445959","phase":"PHASE1, PHASE2","title":"Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-08-29","conditions":"Mutant IDH1 Inhibitor Olutasidenib","enrollment":78},{"nctId":"NCT05360160","phase":"PHASE1, PHASE2","title":"A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-10-14","conditions":"Acute Myeloid Leukemia","enrollment":43},{"nctId":"NCT05396859","phase":"PHASE1","title":"Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2022-10-28","conditions":"Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":13},{"nctId":"NCT04878432","phase":"PHASE2","title":"STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-03-17","conditions":"Myelodysplastic Syndrome (MDS)","enrollment":39},{"nctId":"NCT05148234","phase":"PHASE1, PHASE2","title":"BMS-986253 in Myelodysplastic Syndromes","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-29","conditions":"Myelodysplastic Syndromes","enrollment":2},{"nctId":"NCT02998567","phase":"PHASE1","title":"Combination Study of Guadecitabine/ASTX727 and Pembrolizumab","status":"RECRUITING","sponsor":"Royal Marsden NHS Foundation Trust","startDate":"2017-01-26","conditions":"Non Small Cell Lung Cancer","enrollment":60},{"nctId":"NCT04980404","phase":"PHASE1","title":"Inqovi Maintenance Therapy in Myeloid Neoplasms","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2021-09-17","conditions":"Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Stem Cell Leukemia","enrollment":22},{"nctId":"NCT04857645","phase":"PHASE2","title":"ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients","status":"COMPLETED","sponsor":"Groupe Francophone des Myelodysplasies","startDate":"2021-06-22","conditions":"MDS, AML","enrollment":57},{"nctId":"NCT06802146","phase":"EARLY_PHASE1","title":"Early Intervention in High Risk CCUS","status":"RECRUITING","sponsor":"Lachelle D. Weeks, MD, PhD","startDate":"2025-02-07","conditions":"Clonal Cytopenia of Undetermined Significance, Cytopenia","enrollment":108},{"nctId":"NCT06351306","phase":"PHASE2","title":"DEC-C and Thioguanine for R/R AML","status":"WITHDRAWN","sponsor":"Columbia University","startDate":"2024-04-01","conditions":"Acute Myeloid Leukemia","enrollment":""},{"nctId":"NCT05883956","phase":"PHASE3","title":"A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Otsuka Australia Pharmaceutical Pty Ltd","startDate":"2023-12-20","conditions":"Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic","enrollment":13},{"nctId":"NCT03906695","phase":"PHASE1","title":"Phase 1 Trial of ASTX727 in Subjects With Lower-risk Myelodysplastic Syndromes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2019-03-15","conditions":"Lower-risk Myelodysplastic","enrollment":30},{"nctId":"NCT02649790","phase":"PHASE1, PHASE2","title":"Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications","status":"COMPLETED","sponsor":"Karyopharm Therapeutics Inc","startDate":"2016-01","conditions":"Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Metastatic Castration-Resistant Prostate Cancer (mCRPC)","enrollment":277},{"nctId":"NCT06113289","phase":"PHASE1, PHASE2","title":"A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid Leukemia","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-02-08","conditions":"Acute Myeloid Leukemia","enrollment":""},{"nctId":"NCT05835011","phase":"PHASE2","title":"A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)","status":"TERMINATED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2023-06-27","conditions":"Myelodysplastic Syndromes","enrollment":2},{"nctId":"NCT03306264","phase":"PHASE3","title":"Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML","status":"COMPLETED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2018-02-15","conditions":"Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia","enrollment":227},{"nctId":"NCT02103478","phase":"PHASE1, PHASE2","title":"Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)","status":"COMPLETED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2014-10-28","conditions":"Myelodysplastic Syndrome, MDS","enrollment":130},{"nctId":"NCT04155580","phase":"PHASE1","title":"A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)","status":"TERMINATED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2020-06-12","conditions":"Acute Myeloid Leukemia","enrollment":68},{"nctId":"NCT03813186","phase":"PHASE1","title":"Effect of Food on Blood Levels of ASTX727","status":"COMPLETED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2018-11-08","conditions":"Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia","enrollment":18},{"nctId":"NCT06357858","phase":"PHASE1","title":"ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck","status":"WITHDRAWN","sponsor":"Case Comprehensive Cancer Center","startDate":"2024-06-01","conditions":"Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma","enrollment":""},{"nctId":"NCT04134884","phase":"PHASE1","title":"Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Kathy Miller","startDate":"2020-04-01","conditions":"Metastatic Breast Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Tumor","enrollment":34},{"nctId":"NCT05456269","phase":"PHASE1","title":"A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS","status":"WITHDRAWN","sponsor":"Race Oncology Ltd","startDate":"2022-07-29","conditions":"Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":""},{"nctId":"NCT04985656","phase":"PHASE2","title":"A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes","status":"WITHDRAWN","sponsor":"Takeda","startDate":"2021-10-01","conditions":"Myelodysplastic Syndromes (MDS)","enrollment":""},{"nctId":"NCT04013880","phase":"PHASE1, PHASE2","title":"ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia","status":"WITHDRAWN","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2019-08-27","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ANGLE CLOSURE GLAUCOMA"},{"count":1,"reaction":"CHOROIDAL EFFUSION"},{"count":1,"reaction":"CONDITION AGGRAVATED"}],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ASTX727","ASTX 727","ASTX-727","C-DEC","CDA Inhibitor E7727/Decitabine Combination Agent ASTX727"],"phase":"marketed","status":"active","brandName":"Decitabine and cedazuridine","genericName":"Decitabine and cedazuridine","companyName":"Race Oncology Ltd","companyId":"race-oncology-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Decitabine inhibits DNA methyltransferase to reactivate silenced tumor suppressor genes, while cedazuridine protects decitabine from deamination, allowing oral administration. Used for Myelodysplastic syndromes (MDS), Acute myeloid leukemia (AML).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}